Live Chat

Live Chat

BD MAX women's health and sexually transmitted infections (STI) assays

Vaginitis is the most common women's health issue, accounting for more than 10 billion cases each year

Hospitals and laboratories are faced with increasing challenges in managing workload and patient needs. Staggering cost to the U.S. healthcare system caused by the growing number of new infections demands action in the way we test for women's health and sexually transmitted infections (STIs).

The BD women's health and sexually transmitted infections portfolio is focused on providing accurate, reliable results enabling clinicians to elevate patient care. The Centers for Disease Control and Prevention (CDC) estimates that 21.2 million bacterial vaginosis (BV) cases and 2.3 million trichomoniasis cases occur per year.1 In addition, the CDC estimates that nearly 75% of all adult women have had at least one yeast infection in their lifetime.2

Vaginitis testing has traditionally included a series of manual, time-consuming laboratory tests to include wet mount examination, culture and Gram staining. Each test has its challenges in terms of low sensitivity and specificity, dependency on operator technique and technician subjectivity in reporting results.

About 20 million new STIs are transmitted in the United States each year, leading to nearly $16 billion in direct medical costs.  

Solution


Accurate treatment begins with an accurate diagnosis. The BD women's health and STI portfolio elevates the standard of care, focusing on accurate, reliable results.  

How we help

BD Affirm VPIII microbial identification system

This system is the first market entry with a molecular, automated test that can detect all three organisms efficiently and accurately from a single swab.

BD MAX system

The BD MAX women's health portfolio elevates the standard of care, focusing on common issues that plague their reproductive health.

Assay offerings by system


BD MAX system
This DNA assay is for the detection of vaginitis and vaginosis (V/V)* (Candida spp., Lactobacillus spp., Gardnerella vaginalis, Atopobium vaginae, BVAB-2, Megasphaera and Trichomonas vaginalis). Q4 2014 (CE), Q2 2015 (FDA).

BD Affirm VPIII microbial identification sytem
This DNA-probe assay is for V/V (trichomonas, Candida spp., Gardernerella vaginalis).

BD Affirm VPIII microbial identification system

The system helps improve accuracy with DNA-probe technology that efficiently detects from a single swab the three organisms most associated with vaginitis.

BD Viper LT system

The BD Viper LT system provides fully automated, integrated molecular testing on a tabletop analyzer.

BD MAX system

The BD MAX system helps redefine staff productivity with a fully integrated, automated molecular platform capable of running both FDA-cleared and open system assays efficiently and flexibly.

BD Viper system with XTR technology

The BD Viper system with XTR technology is a single automated platform that efficiently consolidates five sexually transmitted disease assays.


Notes

* Product under development. Not available for sale or use.

References
  1. Centers for Disease Control and Prevention. Bacterial vaginosis (BV) statistics. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/std/bv/stats.htm. Updated December 17, 2015. Accessed March 30, 2017.
  2. Centers for Disease Control and Prevention. Genital/Vulvovaginal candidiasis (VVC). Centers for Disease Control and Prevention Web site. http://www.cdc.gov/fungal/diseases/candidiasis/genital/statistics.html. Updated February 13, 2014. Accessed March 30, 2017.

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.